Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

BACKGROUND: Prurigo nodularis is a chronic skin disease characterised by intensely pruritic, hyperkeratotic nodules. Vixarelimab, a human monoclonal antibody, binds to the beta subunit of the oncostatin M receptor, inhibiting signalling of both interleukin 31 and oncostatin M, two cytokine pathways...

Descripción completa

Detalles Bibliográficos
Autores principales: Sofen, Howard, Bissonnette, Robert, Yosipovitch, Gil, Silverberg, Jonathan I., Tyring, Stephen, Loo, Wei Jing, Zook, Matthew, Lee, Mark, Zou, Liangxing, Jiang, Guang-Liang, Paolini, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932343/
https://www.ncbi.nlm.nih.gov/pubmed/36816342
http://dx.doi.org/10.1016/j.eclinm.2023.101826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932343/
https://www.ncbi.nlm.nih.gov/pubmed/36816342
http://dx.doi.org/10.1016/j.eclinm.2023.101826

Ejemplares similares